While TSC patients could develop multisystem life-threatening clinical manifestations [12], mTOR inhibitors (i.e. Sirolimus and Everolimus) are found to suppress the progression of multiple disease specific manifestations such as brain or kidney tumours [13], hence are widely used. This evidence concerns the gene MTOR and tuberous sclerosis.